1877 — Shanghai Junshi Biosciences Share News
0.000.00%
Last trade - 00:00- HK$15.67bn
- HK$18.79bn
- CNY2.50bn
Brief: Junshi Biosciences' Prelim 2024 Net Loss At 1.3 Billion Yuan
Brief: Shanghai Junshi Biosciences Gets Approval For Clinical Trial Of AWT020 Sterile Powder
Brief: Junshi Biosciences' Unit Signs Agreements With Leo Pharma
Brief: Junshi Biosciences Announces Toripalimab's Approval In Australia
Brief: Junshi Biosciences Sees 2024 Net Loss Of 1.3 Bln Yuan
Brief: Shanghai Junshi Biosciences Receives Regular Approval Of Deuremidevir Hydrobromide Tablets By Nmpa
Brief: Shanghai Junshi Biosciences Says JS212 Injection Received Acceptance Notice
Brief: Shanghai Junshi Biosciences Says Regular Approval Of Toripalimab As Second-Line Or Later Treatment Of Melanoma By NMPA
Brief: Shanghai Junshi Biosciences Says Toripalimab Injection Were Successfully Included In Category B
Brief: Shanghai Junshi Biosciences Announces Approval By MHRA For Marketing Of Toripalimab
Brief: Shanghai Junshi Biosciences Announces Approval For Marketing Of Toripalimab In Hong Kong
Brief: Shanghai Junshi Biosciences Says Js125 Received Notice Of Approval- For Clinical Trial
Brief: Shanghai Junshi Biosciences Unit Entered Into License, Cooperation Agreement
Brief: Junshi Biosciences Announces European Commission Approval For Marketing Of Toripalimab
Shanghai Junshi Biosciences rises on EC's approval for marketing Toripalimab
Brief: Shanghai Junshi Biosciences Receives Approval By European Commission For Marketing Of Toripalimab
Brief: Shanghai Junshi Biosciences Says May Reduce Registered Capital In Shanghai Junshi Xihai Biotechnology
Brief: Shanghai Junshi Biosciences Says Received Acceptance Notice Issued By NMPA For New Drug Application For Toripalimab
Brief: Shanghai Junshi Biosciences Announces Receipt Of Positive Opinion For Toripalimab